サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1575048

頭蓋内治療デリバリー市場：治療法別、適応症別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年の予測

Intracranial Therapeutic Delivery Market, By Therapy, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 288 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.85円
頭蓋内治療デリバリー市場：治療法別、適応症別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年10月02日
発行: AnalystView Market Insights
ページ情報: 英文 288 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

頭蓋内治療デリバリー市場規模は2023年に19億8,032万米ドルとなり、2024年から2032年にかけてCAGR 7.99％で拡大しました。

この分野の技術革新は、薬剤の正確なターゲティング、徐放性、バイオアベイラビリティの向上を通じて、患者の転帰を改善することを目的としています。研究の進展に伴い、神経用途の遺伝子治療や生物製剤の市場開拓も進んでいます。神経疾患の有病率の増加と医療技術の進歩がこの分野の需要を促進する主な要因であり、現代のヘルスケアにおいて重要な注目分野となっています。

頭蓋内治療デリバリー市場-市場力学

神経疾患の有病率の増加が標的治療への需要を促進

神経疾患の有病率の増加は、頭蓋内治療デリバリー市場の重要な促進要因です。人口の高齢化に伴い、アルツハイマー病、パーキンソン病、多発性硬化症などの疾患が一般的になりつつあり、高度な治療オプションが必要となっています。CDCによると、2020年には米国の成人の推定6人に1人が神経疾患を患っていると報告されています。このような罹患率の増加は、的を絞った効果的な治療を提供できる革新的な治療デリバリーシステムに対する需要を煽るものです。

さらに、認知度の向上と早期診断が、専門的な治療を求める患者の増加に寄与しています。ヘルスケアシステムがこのような課題に対処しようと努力する中、新しい頭蓋内送達方法の研究開発への投資は拡大し、市場成長の機会を生み出すと予想されます。

頭蓋内治療デリバリー市場-主要洞察

弊社リサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約7.99%のCAGRで毎年成長すると推定されます。

治療法別では、遺伝子治療が2023年に最大の市場シェアを示すと予測されました。

適応症別では、多発性硬化症が2023年の主要タイプでした。

地域別では、北米が2023年の売上高をリード

頭蓋内治療デリバリー市場-セグメンテーション分析：

頭蓋内治療デリバリーの世界市場は、治療法、適応症、地域に基づいてセグメント化されます。

市場は治療法に基づき3つのカテゴリーに分けられる：細胞療法、遺伝子療法、酵素補充療法です。遺伝子治療は頭蓋内治療デリバリー市場で最も顕著です。このアプローチは、神経疾患の根本的な遺伝的原因に対処する可能性を提供し、単なる対症療法ではなく長期的な解決策を提供します。ベクター技術やCRISPR遺伝子編集の進歩により、遺伝子治療の有効性と安全性が向上し、遺伝性てんかんや神経変性疾患などの疾患に対する有効性が高まっています。個別化医療への注目の高まりは、個々の遺伝子プロファイルに合わせた治療が可能であることから、遺伝子治療の需要をさらに押し上げています。全体として、その革新的な性質と変革の可能性は、遺伝子治療を市場の主要セグメントとして位置づけています。

市場は適応症別に4つのカテゴリーに分類される：脊髄性筋萎縮症（SMA）、多発性硬化症、バッテン病、筋萎縮性側索硬化症です。多発性硬化症（MS）は、頭蓋内治療デリバリー市場で最も顕著です。MSは世界中で数百万人が罹患しており、その複雑な症状を管理し、病気の進行を遅らせることができる革新的な治療オプションに対する大きな需要につながっています。モノクローナル抗体や経口治療などの治療法の進歩が患者の予後を改善し、市場の成長を促進しています。MSの有病率の増加は、より効果的な治療法の研究とともに、治療法開発の焦点としてのMSの重要性を強調しています。認知度と診断が向上するにつれ、MS関連治療市場は拡大を続け、支配的なセグメントとしての地位を固めています。

頭蓋内治療デリバリー市場-地理的洞察

北米は頭蓋内治療デリバリー市場において最大の地域であり、主要ヘルスケア企業の存在、高度な研究施設、強固な規制枠組みなどがその主な要因となっています。特に米国は、高いヘルスケア支出、技術革新の重視、神経障害を患いやすい高齢化により、大きなシェアを占めています。さらに、有利な償還政策と臨床試験のための確立されたインフラが市場の成長を支えています。

この地域では神経学的研究への投資も増加しており、新しい治療法の開発が促進されています。欧州とアジア太平洋は需要が拡大している新興市場であるが、北米は確立されたヘルスケアエコシステムが引き続きペースを握っており、頭蓋内治療デリバリーの革新を目指す既存企業と新規参入者の双方にとって焦点となっています。

頭蓋内治療デリバリー市場-競合情勢：

頭蓋内治療デリバリー市場は、既存企業と新興バイオテクノロジー企業による激しい競争が特徴です。MedtronicやAbbVieといった主要企業は、先進的なドラッグデリバリーシステムや神経疾患に対する革新的な治療法に注力し、幅広い製品ポートフォリオと強固な研究開発力で圧倒的な強さを見せています。また、ストライカーやボストン・サイエンティフィックは、外科手術用機器の分野で強い存在感を発揮し、治療成果を高めています。

NeuroRx社やZynerba Pharmaceuticals社などの新興企業は、カンナビノイドをベースとした治療法などの新しい治療法を導入しており、市場の展望を多様化しています。イノベーションを加速させ、市場範囲を拡大しようとする企業にとって、提携や戦略的パートナーシップは一般的です。規制上の課題と臨床検証の必要性は依然として重要なハードルであり、競合戦略に影響を与えています。全体として、技術の進歩や神経疾患への深い理解が新製品開発の原動力となり、市場は成長する態勢を整えています。

目次

第1章 頭蓋内治療デリバリー市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 頭蓋内治療デリバリーの主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 頭蓋内治療デリバリー産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 頭蓋内治療デリバリー市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 頭蓋内治療デリバリー市場情勢

  • 頭蓋内治療デリバリー市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 頭蓋内治療デリバリー市場- 治療法別

  • 概要
    • 治療法別セグメントシェア分析
    • 細胞ベースの治療
    • 遺伝子治療
    • 酵素補充療法

第8章 頭蓋内治療デリバリー市場- 適応症別

  • 概要
    • 適応症別セグメントシェア分析
    • 脊髄性筋萎縮症（SMA）
    • 多発性硬化症
    • バッテン病
    • 筋萎縮性側索硬化症
    • その他

第9章 頭蓋内治療デリバリー市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第10章 主要ベンダー分析- 頭蓋内治療デリバリー業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Medtronic
    • AbbVie
    • Stryker Corporation
    • Baxter International
    • Ipsen SA
    • Johnson &Johnson（Ethicon）
    • NuVasive
    • NeuroRx
    • CureVac AG
    • Boston Scientific
    • Aesculap
    • Zynerba Pharmaceuticals
    • Elekta
    • Intra-Cellular Therapies

第11章 アナリストの全方位展望

目次
Product Code: ANV4050

REPORT HIGHLIGHT

Intracranial Therapeutic Delivery Market size was valued at USD 1,980.32 Million in 2023, expanding at a CAGR of 7.99% from 2024 to 2032.

The intracranial therapeutic delivery market focuses on methods and technologies used to administer treatments directly into the cranial cavity, targeting conditions such as brain tumors, epilepsy, and neurodegenerative disorders. This market encompasses a variety of delivery systems, including implantable devices, infusions, and drug-eluting technologies that optimize therapeutic efficacy and minimize side effects.

Innovations in this field aim to improve patient outcomes through precise targeting, sustained release, and enhanced bioavailability of medications. As research progresses, the market is also seeing developments in gene therapy and biologics for neurological applications. The growing prevalence of neurological disorders and advances in medical technology are key factors driving demand in this sector, making it a critical area of focus in modern healthcare.

Intracranial Therapeutic Delivery Market- Market Dynamics

Increased prevalence of neurological disorders driving demand for targeted therapies.

The increasing prevalence of neurological disorders is a significant driver for the intracranial therapeutic delivery market. As the population ages, conditions such as Alzheimer's, Parkinson's, and multiple sclerosis are becoming more common, necessitating advanced treatment options. According to the CDC, an estimated 1 in 6 adults in the U.S. reported having a neurological condition in 2020. This rising incidence fuels the demand for innovative therapeutic delivery systems that can provide targeted and effective treatments.

Furthermore, greater awareness and early diagnosis contribute to the growing patient pool seeking specialized care. As healthcare systems strive to address these challenges, investments in research and development for novel intracranial delivery methods are expected to expand, creating opportunities for market growth.

Intracranial Therapeutic Delivery Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.99% over the forecast period (2024-2032)

Based on Therapy segmentation, Gene Therapy, was predicted to show maximum market share in the year 2023

Based on Indication segmentation, Multiple Sclerosis was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

Intracranial Therapeutic Delivery Market- Segmentation Analysis:

The Global Intracranial Therapeutic Delivery Market is segmented based on Therapy, Indication, and Region.

The market is divided into three categories based on Therapy: Cell-based Therapy, Gene Therapy, and Enzyme Replacement Therapy. Gene Therapy is the most prominent in the intracranial therapeutic delivery market. This approach offers the potential to address the underlying genetic causes of neurological disorders, providing long-term solutions rather than just symptomatic relief. Advances in vector technology and CRISPR gene editing are enhancing the efficacy and safety of gene therapies, making them increasingly viable for conditions like genetic forms of epilepsy and neurodegenerative diseases. The growing focus on personalized medicine further propels the demand for gene therapy, as treatments can be tailored to individual genetic profiles. Overall, its innovative nature and transformative potential position gene therapy as a leading segment in the market.

The market is divided into four categories based on Indication: Spinal Muscular Atrophy (SMA), Multiple Sclerosis, Batten Disease, and Amyotrophic Lateral Sclerosis. Multiple Sclerosis (MS) is the most prominent in the intracranial therapeutic delivery market. MS affects millions globally, leading to significant demand for innovative treatment options that can manage its complex symptoms and slow disease progression. Advances in therapies, including monoclonal antibodies and oral treatments, are enhancing patient outcomes and driving market growth. The increasing prevalence of MS, along with ongoing research into more effective delivery methods, underscores its importance as a focal point for therapeutic development. As awareness and diagnosis improve, the market for MS-related treatments continues to expand, solidifying its position as a dominant segment.

Intracranial Therapeutic Delivery Market- Geographical Insights

North America stands out as the largest region in the intracranial therapeutic delivery market, driven primarily by the presence of leading healthcare companies, advanced research facilities, and a robust regulatory framework. The United States, in particular, accounts for a significant share due to high healthcare expenditure, a strong emphasis on innovation, and an aging population prone to neurological disorders. Additionally, favorable reimbursement policies and a well-established infrastructure for clinical trials support market growth.

The region is also witnessing increased investments in neurological research, which fosters the development of new therapeutic modalities. While Europe and Asia-Pacific are emerging markets with growing demand, North America's established healthcare ecosystem continues to set the pace, making it a focal point for both existing players and new entrants looking to innovate in intracranial therapeutic delivery.

Intracranial Therapeutic Delivery Market- Competitive Landscape:

The intracranial therapeutic delivery market is characterized by intense competition among established players and emerging biotech firms. Key companies like Medtronic and AbbVie dominate with their extensive product portfolios and robust R&D capabilities, focusing on advanced drug delivery systems and innovative therapies for neurological conditions. Additionally, Stryker and Boston Scientific leverage their strong presence in surgical devices to enhance therapeutic outcomes.

Emerging players, such as NeuroRx and Zynerba Pharmaceuticals, are introducing novel treatment modalities, including cannabinoid-based therapies, which diversify the market landscape. Collaboration and strategic partnerships are common as companies seek to accelerate innovation and expand their market reach. Regulatory challenges and the need for clinical validation remain critical hurdles, influencing competitive strategies. Overall, the market is poised for growth as advancements in technology and a deeper understanding of neurological diseases drive new product development.

Recent Developments:

In September 2024, CereVasc's endovascular device has the potential to serve as a novel delivery system for gene therapy directly to the brain, improving treatment efficacy for neurological conditions. By utilizing this approach, aims to enhance targeted therapy while minimizing invasiveness and side effects associated with traditional methods.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Medtronic
  • AbbVie
  • Stryker Corporation
  • Baxter International
  • Ipsen S.A.
  • Johnson & Johnson (Ethicon)
  • NuVasive
  • NeuroRx
  • CureVac AG
  • Boston Scientific
  • Aesculap
  • Zynerba Pharmaceuticals
  • Elekta
  • Intra-Cellular Therapies

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY THERAPY- MARKET ANALYSIS, 2019 - 2032

  • Cell-based Therapy
  • Gene Therapy
  • Enzyme Replacement Therapy

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Spinal Muscular Atrophy (SMA)
  • Multiple Sclerosis
  • Batten Disease
  • Amyotrophic Lateral Sclerosis
  • Others

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Intracranial Therapeutic Delivery Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Intracranial Therapeutic Delivery Market Snippet by Therapy
    • 2.1.2. Intracranial Therapeutic Delivery Market Snippet by Indication
    • 2.1.3. Intracranial Therapeutic Delivery Market Snippet by Country
    • 2.1.4. Intracranial Therapeutic Delivery Market Snippet by Region
  • 2.2. Competitive Insights

3. Intracranial Therapeutic Delivery Key Market Trends

  • 3.1. Intracranial Therapeutic Delivery Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Intracranial Therapeutic Delivery Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Intracranial Therapeutic Delivery Market Opportunities
  • 3.4. Intracranial Therapeutic Delivery Market Future Trends

4. Intracranial Therapeutic Delivery Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Intracranial Therapeutic Delivery Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Intracranial Therapeutic Delivery Market Landscape

  • 6.1. Intracranial Therapeutic Delivery Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Intracranial Therapeutic Delivery Market - By Therapy

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy, 2023 & 2032 (%)
    • 7.1.2. Cell-based Therapy
    • 7.1.3. Gene Therapy
    • 7.1.4. Enzyme Replacement Therapy

8. Intracranial Therapeutic Delivery Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Spinal Muscular Atrophy (SMA)
    • 8.1.3. Multiple Sclerosis
    • 8.1.4. Batten Disease
    • 8.1.5. Amyotrophic Lateral Sclerosis
    • 8.1.6. Others

9. Intracranial Therapeutic Delivery Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Intracranial Therapeutic Delivery Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Intracranial Therapeutic Delivery Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Intracranial Therapeutic Delivery Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Intracranial Therapeutic Delivery Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Intracranial Therapeutic Delivery Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Intracranial Therapeutic Delivery Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Medtronic
    • 10.2.2. AbbVie
    • 10.2.3. Stryker Corporation
    • 10.2.4. Baxter International
    • 10.2.5. Ipsen S.A.
    • 10.2.6. Johnson & Johnson (Ethicon)
    • 10.2.7. NuVasive
    • 10.2.8. NeuroRx
    • 10.2.9. CureVac AG
    • 10.2.10. Boston Scientific
    • 10.2.11. Aesculap
    • 10.2.12. Zynerba Pharmaceuticals
    • 10.2.13. Elekta
    • 10.2.14. Intra-Cellular Therapies

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us